Evaluación de la susceptibilidad a colistín y meropenem en Klebsiella pneumoniae productoras de carbapenemasas - KPC
Bol. venez. infectol
;
31(1): 37-41, ene-jun 2020.
Artigo
em Espanhol
|
LILACS-Express
| LILACS
| ID: biblio-1123250
ABSTRACT
The increase in infections caused by Enterobacterales resistant to carbapenems and other antimicrobials has limited the therapeutic alternatives which have led to the recovery of the use of colistin in clinical practices. Since 2015, a mechanism that confers resistance to colistin through plasmids related to the mcr-1 gene (Mobile Colistin Resistance) was detected, increasing the importance of its susceptibility test in the laboratory. Colistin susceptibility was evaluated by the disk elution method in 24 strains of Carbapenemase-producing type KPC Klebsiella pneumoniae, resulting 4 strains (17 %) resistant to colistin and 20 strains (83 %) intermediate. Also, in these strains, sensitivity to meropenem was evaluated by the E-test® method, finding that 10 strains (41,6 %) were within the acceptable range for their combination with colistin, 5 strains (20, 8 %) were within the uncertain range and 9 strains (37,4 %) were not appropriate for combination with colistin. For the combination of colistin with meropenem to be considered as a therapeutic alternative the MIC of colistin must be ≤ 2 µg /mL with meropenem ≤8 µg /mL, while the MIC between 12-16 µg/mL of meropenem may or not may work; and with a MIC of 32 µg/mL meropenem, the combination is not effective.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Idioma:
Espanhol
Revista:
Bol. venez. infectol
Assunto da revista:
Doenças Transmissíveis
Ano de publicação:
2020
Tipo de documento:
Artigo
País de afiliação:
Venezuela
Instituição/País de afiliação:
Cátedra de Microbiología/VE
/
Instituto Médico La Floresta/VE
Similares
MEDLINE
...
LILACS
LIS